The risk of DR progression as related to mean HbA1c during DCCT

Slides:

Advertisements

Similar presentations

For(int i = 1; i

Advertisements

Electronic patient record since SDC Quality of Care Data 2009 – 2011 for Type 1 Diabetes NCQA indicatorGoal HbA1c > 9,0 %≤ 15%

Copyright © 2008 American Medical Association. All rights reserved.

Copyright © 2017 American Academy of Pediatrics.

New Patient-Friendly Options for Managing Insulin Dosing

The cumulative incidence of any major eye disease end point (PDR, CSME, application of laser, or development of blindness) is shown in relation to diabetes.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.

Similarities Differences

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

Participant flow diagram for the ‘GNHIES98—longitudinal sample’ and the ‘DEGS1—cross-sectional sample’. Participant flow diagram for the ‘GNHIES98—longitudinal.

The concept of immortal time bias is depicted schematically using the cohort study from the Taiwanese National Health Insurance data during 2000–2007:

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.

The effect of PAD and infection on outcome of cast treatment

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

The Kaplan-Meier curves display the time to event for the primary outcome (A) and total mortality (B) during follow-up from randomization until the end.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effect of empagliflozin on efficacy parameters at week 18.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Difference in average school grades between offspring born to women with type 1 diabetes and the matched control children, by maternal third trimester.

Percentage of patients with diabetes achieving HbA1c

HbA1c differences between intensively and conventionally treated patients in major clinical trials, with baseline to endpoint HbA1c level in type 1 diabetes.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Progression to micro- or macroalbuminuria.

Visualization of prescriptive algorithm: provider dashboard prototype.

A: Typical course of a normal sympathetic vasomotor response as recorded by continuous wave Doppler sonography. A: Typical course of a normal sympathetic.

Plots of average estimated and measured GFR vs

A: Probability of retinopathy-free survival.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Dr Naader Noory`s formulas about diabetes mellitus.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

ROC curves showing the performance of the Diabetes Risk Score in predicting diabetes in the 1987 and 1992 cohorts; follow-up of both cohorts continued.

Differences in the values of HbA1c variables between the retinopathy-positive and retinopathy-negative groups at year 20. Differences in the values of.

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

Risk of mortality in patients with diabetes and ESRD

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Sensitivity and specificity of HbA1c, FPG, and 2hPG in identifying persons who developed diabetes within 10 years of screening among children and adolescents.

Presentation transcript:

The risk of DR progression as related to mean HbA1c during DCCT The risk of DR progression as related to mean HbA1c during DCCT. The rate of DR progression per 100 patient-years (100 PYR) was similar and highly associated with HbA1c in the DCCT for both the INT and the CON groups (12). The risk of DR progression as related to mean HbA1c during DCCT. The rate of DR progression per 100 patient-years (100 PYR) was similar and highly associated with HbA1c in the DCCT for both the INT and the CON groups (12). Lloyd Paul Aiello, and for the DCCT/EDIC Research Group Dia Care 2014;37:17-23 ©2014 by American Diabetes Association